Olatoyosi Sobulo Odenike, MD, is an expert in the care of adults with leukemia, chronic myeloproliferative diseases, and myelodysplastic syndromes. She specializes in all types of treatment for these diseases, including blood and bone marrow stem cell transplant.
An active researcher, Dr. Odenike is involved in the development of novel therapeutic agents for the treatment of acute and chronic leukemias and chronic myeloproliferative diseases. The ultimate goal of her research is to improve treatment options for patients with these diseases. Dr. Odenike is the principal investigator on a number of clinical trials investigating molecularly targeted agents in this patient population. These clinical trials also integrate laboratory studies to evaluate the effect that these agents have on cancer cells.
An active researcher, Dr. Odenike is involved in the development of novel therapeutic agents for the treatment of acute and chronic leukemias and chronic myeloproliferative diseases. The ultimate goal of her research is to improve treatment options for patients with these diseases. Dr. Odenike is the principal investigator on a number of clinical trials investigating molecularly targeted agents in this patient population. These clinical trials also integrate laboratory studies to evaluate the effect that these agents have on cancer cells.
Specialties
Areas of Expertise
Board Certifications
- Medical Oncology
Memberships & Medical Societies
- American Association for the Advancement of Science
- American Society of Hematology
- American Society of Clinical Oncology
Practicing Since
- 2000
Languages Spoken
- English
Medical Education
- University of Ibadan College of Medicine
Internship
- University of Illinois at Chicago
Residency
- University of Illinois at Chicago
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
- Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
- Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
- Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
- Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
- APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
- Decitabine in Treating Patients With Myelofibrosis
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
- A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
- Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
- Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient